IDH1 and acute myeloid leukemia: Overall, there were no differences in OS or EFS in patients with IDH1/2-mutated vs. WT AML (44.5% vs. 43.3% Figure 2A, and 36.1% vs. 26.6%, Figure 2B, respectively).